source
- Amgen's Sjögren's drug dazodalibep meets primary endpoint in Phase 3 trialAmgen reported that its experimental therapy for Sjögren's disease, dazodalibep, achieved the primary goal in a late‑stage study. The Phase 3 OASIZ 301 trial enrolled roughly 621 patients with mod…
- Novartis signs up to $900 million deal with China's BoomRay for preclinical radioligand therapyNovartis has licensed a preclinical radioligand therapy from BoomRay Pharmaceuticals, a Suzhou‑based biotech, in a deal that could be worth up to $900 million. The agreement includes an undisclose…